Altre lingue Vir Biotechnology, Inc.

Azioni

VIR

US92764N1028

Tempo reale stimato Cboe BZX Altri mercati azionari 16:18:02 11/06/2024			Variaz. 5gg	Var. 1 gen.
10,88 ^USD	-2,99%		+3,40%	+8,75%

06/06	VIR BIOTECHNOLOGY, INC. : ancora rating Neutral per Morgan Stanley	ZM
05/06	Aggiornamento settoriale: i titoli del settore sanitario sono stabili nel premercato di mercoledì	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Vir Biotechnology - Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus	06/06
Sector Update: Health Care Stocks Steady Premarket Wednesday	05/06
Sector Update: Health Care	05/06
Exchange-Traded Funds, Equity Futures Higher Pre-Bell as Focus Shifts to Market Reports This Week	05/06
Vir Biotechnology Says Mid-Stage Trial for Tobevibart, Elebsiran Show Clinically Significant Efficacy	05/06
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment	05/06
Vir Biotechnology, Inc. Announces New Preliminary Data from its Phase 2 SOLSTICE Hepatitis Delta Clinical Trial Evaluating tobevibart, an Investigational Monoclonalantibody, and Elebsiran	05/06
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	29/05
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer	29/05
Vir Biotechnology, Inc. Appoints Mark D. Eisner as Executive Vice President and Chief Medical Officer, Effective June 3, 2024	29/05
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders	23/05
Multiple Abstracts highlighting Vir Biotechnology's Latest Hepatitis Delta and B Data Accepted for Presentation at the EASL Congress 2024	23/05
Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024	22/05
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024	21/05
Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $56.4M, vs. Street Est of $11.7M	02/05
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results	02/05
Vir Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024	30/04
Cytokinetics Appoints Sung Lee as CFO	26/04
Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Chief Financial Officer, Effective May 3, 2024	18/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Vir Biotechnology, Inc.

Azioni

VIR

US92764N1028

Altre lingue

Filtri